Scientists have identified a new marker for breast cancer prognosis
最近審查：14.06.2024
所有iLive內容都經過醫學審查或事實檢查，以確保盡可能多的事實準確性。
我們有嚴格的採購指南，只鏈接到信譽良好的媒體網站，學術研究機構，並儘可能與醫學同行評審的研究相關聯。 請注意括號中的數字（[1]，[2]等）是這些研究的可點擊鏈接。
如果您認為我們的任何內容不准確，已過時或有疑問，請選擇它並按Ctrl + Enter。
A protein called RPGRIP1L (retinitis pigmentosa GTPase regulator interacting protein 1-like) performs various functions important for development and health throughout life. Mutations in the RPGRIP1L gene are associated with various diseases.
A new study published in the FASEB Journal indicates that RPGRIP1L gene expression levels may serve as a new prognostic marker for patients with invasive breast cancer.
When studying breast tissue samples from different women, the researchers found that RPGRIP1L expression was increased in invasive breast cancer samples compared to normal breast tissue. Additionally, among patients with invasive breast cancer, those with high expression of the RPGRIP1L gene had shorter survival times compared to patients with low expression. Moreover, increased RPGRIP1L expression was correlated with a number of unfavorable clinicopathological features, such as the presence of more aggressive forms of cancer and larger tumors.
The researchers also identified 50 genes and 15 proteins whose expression was positively correlated with RPGRIP1L expression. Most of these proteins and genes were involved in various aspects of the immune response and metabolism.
Finally, the team found that four compounds used against cancer—abrin, epigallocatechin gallate, gentamicin, and tretinoin—showed potential to reduce RPGRIP1L expression in laboratory experiments.
“The results of our study highlight the potential of RPGRIP1L as a meaningful prognostic biomarker for breast cancer and suggest the viability of new therapeutic strategies that may modify the course of the disease, thereby potentially improving survival rates among affected patients,” said study co-author Ph.D. Jie Zeng is from the First Affiliated Hospital of Hunan Normal University in China.